Table 1 Comparison of baseline characteristics before and after propensity score matching
| Â | Before matching | After matching | ||||||
|---|---|---|---|---|---|---|---|---|
Indobufen group (n = 689) | Aspirin group (n = 6446) | P | ASD | Indobufen group (n = 662) | Aspirin group (n = 662) | P | ASD | |
Age, yrs | 66.3 (9.5) | 63.2 (10.6) |  < 0.001 | 0.306 | 66.0 (9.4) | 66.0 (10.5) | 0.991 | 0.001 |
Gender |  |  |  < 0.001 | 0.157 |  |  | 0.626 | 0.030 |
 Male | 495 (71.8) | 5066 (78.6) |  |  | 478 (72.2) | 469 (70.8) |  |  |
 Female | 194 (28.2) | 1380 (21.4) |  |  | 184 (27.8) | 193 (29.2) |  |  |
BMI, kg/m2 | 24.8 (3.3) | 25.0 (3.4) | 0.105 | 0.066 | 24.8 (3.3) | 24.8 (3.5) | 0.806 | 0.014 |
Hypertension | 456 (66.2) | 4162 (64.6) | 0.423 | 0.034 | 437 (66.0) | 424 (64.0) | 0.489 | 0.041 |
Diabetes | 231 (33.5) | 2109 (32.7) | 0.699 | 0.017 | 221 (33.4) | 222 (33.5) | 1.000 | 0.003 |
Hyperlipidemia | 166 (24.1) | 1538 (23.9) | 0.929 | 0.005 | 160 (24.2) | 152 (23.0) | 0.650 | 0.028 |
Current smoker | 119 (17.3) | 1261 (19.6) | 0.163 | 0.059 | 117 (17.7) | 109 (16.5) | 0.609 | 0.032 |
Previous MI | 91 (13.2) | 1067 (16.6) | 0.027 | 0.094 | 89 (13.4) | 91 (13.7) | 0.936 | 0.009 |
Previous stroke | 54 (7.8) | 401 (6.2) | 0.117 | 0.063 | 51 (7.7) | 44 (6.6) | 0.523 | 0.041 |
Previous PCI | 172 (25.0) | 1956 (30.3) | 0.004 | 0.121 | 168 (25.4) | 160 (24.2) | 0.656 | 0.028 |
Previous CABG | 8 (1.2) | 85 (1.3) | 0.865 | 0.014 | 8 (1.2) | 8 (1.2) | 1.000 |  < 0.001 |
CKD | 100 (14.5) | 631 (9.8) |  < 0.001 | 0.145 | 95 (14.4) | 92 (13.9) | 0.875 | 0.013 |
Gastrointestinal diseases | 251 (36.4) | 285 (4.4) |  < 0.001 | 0.865 | 224 (33.8) | 214 (32.3) | 0.599 | 0.032 |
ARC-HBR | 186 (27.0) | 1094 (17.0) |  < 0.001 | 0.244 | 175 (26.4) | 198 (29.9) | 0.179 | 0.077 |
SBP, mmHg | 133.3 (18.0) | 132.9 (19.0) | 0.665 | 0.018 | 133.2 (17.9) | 133.5 (19.6) | 0.782 | 0.015 |
DBP, mmHg | 77.7 (11.4) | 78.3 (10.9) | 0.181 | 0.053 | 77.6 (11.4) | 78.1 (11.3) | 0.506 | 0.037 |
Heart rate, bpm | 75.2 (11.4) | 75.0 (11.3) | 0.574 | 0.022 | 75.2 (11.5) | 75.6 (11.3) | 0.478 | 0.039 |
Diagnosis at admission | Â | Â | 0.104 | 0.098 | Â | Â | 0.787 | 0.057 |
 Stable angina | 398 (57.8) | 3854 (59.8) |  |  | 385 (58.2) | 395 (59.7) |  |  |
 Unstable angina | 191 (27.7) | 1528 (23.7) |  |  | 179 (27.0) | 165 (24.9) |  |  |
NSTEMI | 65 (9.4) | 703 (10.9) | Â | Â | 65 (9.8) | 64 (9.7) | Â | Â |
STEMI | 35 (5.1) | 361 (5.6) | Â | Â | 33 (5.0) | 38 (5.7) | Â | Â |
ACS | 291 (42.2) | 2592 (40.2) | Â | Â | 277 (41.8) | 267 (40.3) | Â | Â |
Primary PCI | 28 (4.1) | 260 (4.0) | 1.000 | 0.002 | 26 (3.9) | 28 (4.2) | 0.889 | 0.015 |
Radial artery access | 676 (98.1) | 6320 (98.0) | 1.000 | 0.005 | 13 (2.0) | 11 (1.7) | 0.837 | 0.023 |
Multivessel disease | 467 (67.8) | 4610 (71.5) | 0.044 | 0.081 | 453 (68.4) | 452 (68.3) | 1.000 | 0.003 |
Target vessel | Â | Â | 0.787 | 0.059 | Â | Â | 0.957 | 0.057 |
 Left main | 4 (0.6) | 40 (0.6) |  |  | 4 (0.6) | 4 (0.6) |  |  |
 Left anterior descending | 274 (39.7) | 2425 (37.6) |  |  | 263 (39.7) | 261 (39.4) |  |  |
 Left circumflex | 82 (11.9) | 781 (12.1) |  |  | 80 (12.1) | 83 (12.5) |  |  |
 Right coronary artery | 152 (22.1) | 1524 (23.7) |  |  | 142 (21.5) | 154 (23.3) |  |  |
 Grafts | 2 (0.3) | 9 (0.1) |  |  | 2 (0.3) | 2 (0.3) |  |  |
 Multiple | 175 (25.4) | 1667 (25.9) |  |  | 171 (25.8) | 158 (23.9) |  |  |
Lesion characteristics | ||||||||
 Burfication | 110 (16.0) | 993 (15.4) | 0.740 | 0.015 | 105 (15.9) | 102 (15.4) | 0.880 | 0.012 |
 Calcified | 84 (12.2) | 643 (10.0) | 0.078 | 0.071 | 79 (11.9) | 85 (12.8) | 0.677 | 0.028 |
 In-stent restenosis | 45 (6.5) | 486 (7.5) | 0.378 | 0.039 | 43 (6.5) | 27 (4.1) | 0.065 | 0.108 |
 Chronic total occlusion | 77 (11.2) | 891 (13.8) | 0.061 | 0.080 | 75 (11.3) | 75 (11.3) | 1.000 |  < 0.001 |
PCI strategy | Â | Â | 0.826 | 0.025 | Â | Â | 0.818 | 0.035 |
 PTCA | 9 (1.3) | 100 (1.6) |  |  | 9 (1.4) | 10 (1.5) |  |  |
 Stent implantation | 620 (90.0) | 5812 (90.2) |  |  | 595 (89.9) | 600 (90.6) |  |  |
 Drug-coated balloon | 60 (8.7) | 534 (8.3) |  |  | 58 (8.8) | 52 (7.9) |  |  |
Intravenous GPI | 82 (11.9) | 1005 (15.6) | 0.012 | 0.107 | 79 (11.9) | 81 (12.2) | 0.933 | 0.009 |
LVEF, % | 61.3 (7.6) | 60.6 (7.7) | 0.024 | 0.091 | 61.2 (7.7) | 61.4 (7.0) | 0.579 | 0.031 |
Hemoglobin, g/L | 130.0 (16.9) | 134.0 (15.4) |  < 0.001 | 0.246 | 130.1 (17.0) | 129.6 (16.3) | 0.584 | 0.030 |
Platelet, × 109/L | 189.0 (158.0, 232.0) | 191.0 (157.0, 235.0) | 0.617 | 0.021 | 189.0 (158.0, 233.0) | 189.0 (159.0, 239.0) | 0.607 | 0.035 |
Serum creatinine, μmol/L | 82.0 (71.0, 94.0) | 81.0 (70.0, 92.0) | 0.044 | 0.060 | 82.0 (71.0, 94.0) | 81.0 (69.0, 93.0) | 0.188 | 0.009 |
Positive FOBT | 152 (22.1) | 718 (11.1) |  < 0.001 | 0.297 | 142 (21.5) | 140 (21.1) | 0.946 | 0.007 |
P2Y12 receptor antagonist |  |  |  < 0.001 | 0.272 |  |  | 1.000 |  < 0.001 |
 Clopidogrel | 536 (77.8) | 4231 (65.6) |  |  | 510 (77.0) | 510 (77.0) |  |  |
 Ticagrelor | 153 (22.2) | 2215 (34.4) |  |  | 152 (23.0) | 152 (23.0) |  |  |
Statin | 676 (98.1) | 6354 (98.6) | 0.432 | 0.036 | 652 (98.5) | 649 (98.0) | 0.674 | 0.035 |
Ezetimibe | 102 (14.8) | 910 (14.1) | 0.665 | 0.020 | 98 (14.8) | 103 (15.6) | 0.759 | 0.021 |
Fenofibrate | 9 (1.3) | 83 (1.3) | 1.000 | 0.002 | 9 (1.4) | 6 (0.9) | 0.604 | 0.043 |
PCSK9i | 6 (0.9) | 98 (1.5) | 0.236 | 0.060 | 6 (0.9) | 2 (0.3) | 0.287 | 0.078 |
RASI | 365 (53.0) | 3555 (55.2) | 0.294 | 0.044 | 352 (53.2) | 336 (50.8) | 0.409 | 0.048 |
ARNI | 35 (5.1) | 440 (6.8) | 0.095 | 0.074 | 35 (5.3) | 29 (4.4) | 0.522 | 0.042 |
Î’eta-blocker | 458 (66.5) | 4552 (70.6) | 0.027 | 0.089 | 440 (66.5) | 442 (66.8) | 0.954 | 0.006 |
Ivabradine | 9 (1.3) | 74 (1.1) | 0.856 | 0.014 | 9 (1.4) | 7 (1.1) | 0.801 | 0.028 |
CCB | 226 (32.8) | 1907 (29.6) | 0.087 | 0.069 | 214 (32.3) | 222 (33.5) | 0.682 | 0.026 |
Nitrate | 222 (32.2) | 2131 (33.1) | 0.687 | 0.018 | 205 (31.0) | 210 (31.7) | 0.813 | 0.016 |
Diuretic | 53 (7.7) | 490 (7.6) | 0.992 | 0.003 | 50 (7.6) | 53 (8.0) | 0.837 | 0.017 |
PPI | 482 (70.0) | 2606 (40.4) |  < 0.001 | 0.622 | 458 (69.2) | 460 (69.5) | 0.952 | 0.007 |